Cost-Effectiveness Evidence on Approved Cancer Drugs in Ireland (pmc.ncbi.nlm.nih.gov)

• NCPE assessments are central to HSE reimbursement decisions for cancer drugs.
• Methodology includes QALY analysis and budget impact modeling.
• Reviews highlight the trade-off between patient access and cost containment.

"This article reviews the cost-effectiveness assessments conducted by Ireland's National Centre for Pharmacoeconomics (NCPE) for approved cancer drugs. These appraisals are pivotal in shaping reimbursement decisions by the HSE, directly influencing patient access and the allocation of health resources. The review covers the methodology, outcomes, and implications of NCPE evaluations for the Irish healthcare system."